Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | PRKCA | P17252 | 6/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | BTN3A1 | O00481 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ARG1 | P05089 | 1/20 | 0.33 |
| ▸ | ARG2 | P78540 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13686742 | 0.95 | ALDH1A1 (0.45) | POLBGAANPSR1ALDH1A1PRKCA | |
| SCHEMBL13824267 | 0.94 | CYP4F2 (0.38) | POLBGAANPSR1ALDH1A1PRKCA | |
| SCHEMBL12901620 | 0.94 | CYP4F2 (0.38) | POLBGAANPSR1ALDH1A1PRKCA | |
| SCHEMBL20286477 | 0.93 | ALDH1A1 (0.48) | POLBGAANPSR1ALDH1A1PRKCA | |
| SCHEMBL7989588 | 0.91 | POLB (0.46) | POLBGAANPSR1ALDH1A1PRKCA | |
| SCHEMBL12901631 | 0.88 | PRKCA (0.38) | POLBGAANPSR1ALDH1A1PRKCA | |
| SCHEMBL4156487 | 0.86 | POLB (0.43) | POLBGAANPSR1ALDH1A1PRKCA | |
| SCHEMBL27819169 | 0.85 | POLB (0.46) | POLBGAANPSR1ALDH1A1PRKCA | |
| SCHEMBL29049106 | 0.83 | POLB (0.44) | POLBGAANPSR1ALDH1A1PRKCA | |
| SCHEMBL9937156 | 0.83 | ALDH1A1 (0.38) | ALDH1A1TSHRTDP1ARG1ARG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180170855-A1 | TREPROSTINIL DERIVATIVES AND COMPOSITIONS AND USES THEREOF | Corsair Pharma, Inc. | 2018-06-21 | — | — | US | disclosed |
| US-9434796-B2 | Catalyst composition with alkoxyalkyl ester internal electron donor and polymer from same | W. R. GRACE & CO.-CONN. (US) | 2016-09-06 | — | — | US | disclosed |
| CN-103380149-B | Produce method and the product with the procatalyst composition of electron donor in alkoxy alkyl | 格雷斯公司 | 2016-07-06 | — | — | CN | disclosed |
| US-9382343-B2 | Procatalyst composition with alkoxypropyl ester internal electron donor and polymer from same | W. R. GRACE & CO.-CONN. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9382343-B2 | Procatalyst composition with alkoxypropyl ester internal electron donor and polymer from same | W. R. GRACE & CO.-CONN. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9382343-B2 | Procatalyst composition with alkoxypropyl ester internal electron donor and polymer from same | W. R. GRACE & CO.-CONN. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9382342-B2 | Procatalyst composition with alkoxyalkyl 2-propenoate internal electron donor and polymer from same | W. R. GRACE & CO.-CONN. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9315592-B2 | Process for producing procatalyst composition with alkoxyalkyl ester internal electron donor and product | W. R. GRACE & CO.-CONN. (US) | 2016-04-19 | — | — | US | disclosed |
| CN-103380152-B | There is the raw catalyst composition of electron donor(ED) in alkoxyalkyl 2-acrylate and polymkeric substance prepared therefrom | W.R. GRACE & CO.-CONN. (US) | 2016-01-20 | — | — | CN | disclosed |
| EP-2655435-B1 | PROCATALYST COMPOSITION WITH ALKOXYALKYL 2-PROPENOATE INTERNAL ELECTRON DONOR AND POLYMER FROM SAME | GRACE W R & CO (US) | 2015-09-23 | — | — | EP | disclosed |
| US-6225460-B1 | PHOSPHOAMIDATE OR ESTER BOND THAT IS HYDROLYZED IN VIVO TO YIELD A CORRESPONDING PHOSPHONATE NUCLEOTIDE ANALOG. | GILEAD SCIENCES, INC. | 2001-05-01 | — | — | US | disclosed |
| US-5886179-A | NUCLEOTIDE PHOSPHONATE ESTERS HYDROLYZABLE IN VIVO TO THE CORRESPONDING NUCLEOTIDE PHOSPHONATE AS VIRICIDES | GILEAD SCIENCES, INC. (US) | 1999-03-23 | — | — | US | disclosed |
| EP-0874858-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1998-11-04 | — | — | EP | disclosed |
| US-5798340-A | ANTITUMOR/ANTINEOPLASTIC ACTIITY, VIRICIDES; BROAD SPECTRUM MICROBIOCIDES; THIOPHOSPHONATES HYDROLYZABLE IN VIVO; ORAL ADMINISTRATION; BIOAVAILABILITY; NONTOXIC; POTENCY | GILEAD SCIENCES, INC. (US) | 1998-08-25 | — | — | US | disclosed |
| US-5656745-A | AMIDATE LINKAGE; ANTITUMOR, ANTICARCINOGENIC AGENTS | GILEAD SCIENCES, INC. (US) | 1997-08-12 | — | — | US | disclosed |
| WO-1997024361-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1997-07-10 | — | — | WO | disclosed |
| EP-0719274-A1 | METHOD FOR DOSING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 1996-07-03 | — | — | EP | disclosed |
| EP-0719273-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1996-07-03 | — | — | EP | disclosed |
| WO-1995007920-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1995-03-23 | — | — | WO | disclosed |
| WO-1995007919-A1 | METHOD FOR DOSING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 1995-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180170855-A1 | TREPROSTINIL DERIVATIVES AND COMPOSITIONS AND USES THEREOF | PTGIS, PTGIR, PDE3A | POLB 758/4885GAA 1269/4885NPSR1 1252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.